IASO Biotheraputics’ CT120 Granted Orphan Drug Designation by the U.S. FDA

SAN JOSE, Calif., NANJING, China and SHANGHAI: SAN JOSE, Calif., NANJING, China and SHANGHAI, Nov. 25, 2021 /PRNewswire/ -- IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company focusing on discovering, developing, and manufacturing innovative medicine announced on Oct 26, 2021 that the Office of Orphan Products Development (OOPD) of the...

Click to view original post